Certara, Inc. (CERT)

NMS – Real vaqt narxi. Valyuta: USD

5.09

-0.04 (-0.78%)

Yopilishda: May 12, 2026, 4:00 PM EDT

5.14

+0.05 (0.98%)

Bozor oldidan: May 13, 2026, 7:00 AM EDT

12.05.2026

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara's executive officers and whether investor losses may be recovered under federal securities laws.

11.05.2026

Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript

11.05.2026

Certara Q1 Earnings Call Highlights

Certara NASDAQ: CERT reported first-quarter 2026 revenue of $106.9 million, up 1% from the prior-year period, as stronger software performance offset softer services results and the company outlined a strategic reset under Chief Executive Officer Jon Resnick.

11.05.2026

Certara, Inc. (CERT) Q1 Earnings Miss Estimates

Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.14 per share a year ago.

11.05.2026

Certara Reports First Quarter 2026 Financial Results

Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business

07.05.2026

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

LAVAL, Québec & RADNOR, Pa.--(BUSINESS WIRE)-- #Altasciences--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals.

22.04.2026

Certara Strategic Business Divestiture Comes At Right Time, Says Analyst

Certara Inc. (NASDAQ:CERT) shares are up 2.34% on Wednesday as the company announced it has entered into a definitive agreement to sell its Regulatory and Medical Writing business.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

11.05.2026

Certara Reports First Quarter 2026 Financial Results

07.05.2026

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

22.04.2026

Veristat to Acquire Certara's Regulatory and Medical Writing Business

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)-- #Biotech--Veristat (the “Company”), a science-first full-service CRO and consultancy that advances complex therapies through the drug development lifecycle to regulatory submission, announced today its intended acquisition of Certara's Regulatory and Medical Writing business. The team that will join Veristat is known for its white-glove advisory services and deep expertise authoring clinical and non-clinical documents throughout the drug development lifecycle. The ac.

Certara, Inc. (CERT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Certara, Inc. (CERT)

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript

Certara Q1 Earnings Call Highlights

Certara, Inc. (CERT) Q1 Earnings Miss Estimates

Certara Reports First Quarter 2026 Financial Results

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Certara Strategic Business Divestiture Comes At Right Time, Says Analyst

Videolar

No Data

Press-relizlar

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Certara Reports First Quarter 2026 Financial Results

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Veristat to Acquire Certara's Regulatory and Medical Writing Business

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript

Certara Q1 Earnings Call Highlights

Certara, Inc. (CERT) Q1 Earnings Miss Estimates

Certara Reports First Quarter 2026 Financial Results

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Certara Strategic Business Divestiture Comes At Right Time, Says Analyst

Videolar

No Data

Press-relizlar

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Certara Reports First Quarter 2026 Financial Results

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Veristat to Acquire Certara's Regulatory and Medical Writing Business

Search stocks

Certara, Inc. (CERT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Certara, Inc. (CERT)

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript

Certara Q1 Earnings Call Highlights

Certara, Inc. (CERT) Q1 Earnings Miss Estimates

Certara Reports First Quarter 2026 Financial Results

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Certara Strategic Business Divestiture Comes At Right Time, Says Analyst

Videolar

No Data

Press-relizlar

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Certara Reports First Quarter 2026 Financial Results

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Veristat to Acquire Certara's Regulatory and Medical Writing Business

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript

Certara Q1 Earnings Call Highlights

Certara, Inc. (CERT) Q1 Earnings Miss Estimates

Certara Reports First Quarter 2026 Financial Results

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Certara Strategic Business Divestiture Comes At Right Time, Says Analyst

Videolar

No Data

Press-relizlar

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Certara Reports First Quarter 2026 Financial Results

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Veristat to Acquire Certara's Regulatory and Medical Writing Business